BIAS
ORIC icon

Beacon Investment Advisory Services’s Oric Pharmaceuticals ORIC Stock Holding History

Beacon Investment Advisory Services’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,000
Closed -$88.3K – 287
2022
Q4 		$88.3K Hold
15,000
– – ﹤0.01% 276
2022
Q3 		$48K Hold
15,000
– – ﹤0.01% 273
2022
Q2 		$67K Hold
15,000
– – ﹤0.01% 281
2022
Q1 		$80K Hold
15,000
– – ﹤0.01% 296
2021
Q4 		$221K Sell
15,000
-2,556
-15% -$39.9K 0.01% 292
2021
Q3 		$367K Hold
17,556
– – 0.02% 233
2021
Q2 		$311K Hold
17,556
– – 0.01% 257
2021
Q1 		$430K Hold
17,556
– – 0.02% 213
2020
Q4 		$594K Buy
+17,556
New +$504K 0.03% 173

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Beacon Investment Advisory Services's ORIC Position: Q1 2023 in Review

Beacon Investment Advisory Services sold out of Oric Pharmaceuticals (ORIC) in Q1 2023, closing a stake of 15,000 shares — an estimated $88.3K sold.

Beacon Investment Advisory Services first reported a position in ORIC in Q4 2020 and held it in 9 quarters. The position peaked at $594K in Q4 2020. 70 funds tracked by Wall St. Rank hold ORIC as of Q1 2023.

  • Beacon Investment Advisory Services reported no remaining Oric Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Beacon Investment Advisory Services sold 15,000 Oric Pharmaceuticals shares in Q1 2023, an estimated $88.3K.
  • Beacon Investment Advisory Services first reported a position in Oric Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Beacon Investment Advisory Services's Oric Pharmaceuticals position peaked at $594K in Q4 2020.
  • 70 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2023.

Based on Beacon Investment Advisory Services's 13F filing for Q1 2023, filed 4 May 2023.